Owned pharmaceutical company PT Bio Farma to provide Indonesia with 250 million vaccines a year in the future. In early September, Yang Jiechi visited Myanmar and promised to give priority to sharing the vaccine with Myanmar after China successfully developed the vaccine. "For many countries in this region, no matter what dissatisfaction they have with China in the South China Sea or other issues, the Wuhan pneumonia epidemic is the first problem to be solved," said Greg Greg, an expert on Southeast Asia at the Center for Strategic and International Studies (CSIS) in the United States. Gregory Poling told VOA.
They may feel Beijing is being photo color correction services aggressive or unwilling to remain silent in a conflict, but if the Chinese vaccine is the only vaccine they have access to, they will do whatever it takes,” Poulin added. "I'm very concerned about China's choice of the most favored nation for vaccines," Lawrence Gostin, a professor of global public health law at Georgetown University, told VOA. A life-saving vaccine should not involve political and influence considerations.” china vaccine wuhan pneumonia covid-2019 Photo Credit: AP/Dazhi Image Sinovac vaccine Pneumonia ravages Southeast Asia Southeast Asian countries' control of the Wuhan pneumonia epidemic is not ideal.
According to statistics, Indonesia and the Philippines are the countries with the largest number of confirmed cases in the region, with 200,000 and nearly 250,000 confirmed cases respectively. The governments of both countries failed to deal with the outbreak at the beginning, which also drew criticism from the local population. Singapore now has nearly 60,000 confirmed cases. In Myanmar, which has poor public health conditions, there has also been an explosive increase in the outbreak of Wuhan pneumonia recently. "The value of an effective vaccine is immeasurable," Gostin said. "It will be the most important medical resource in recent history. Save lives, restart economies." In the global Wuhan pneumonia vaccine research, the United States, China, and the United Kingdom are all in the forefront. Currently, China has two inactivated vaccines and an adenovirus vector entering Phase III clinical trials.